1. Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases. Issue 7 (16th December 2020) Authors: Sun, Wan; Lirio, Richard A.; Schneider, Jennifer; Aubrecht, Jiri; Kadali, Harisha; Baratta, Mike; Gulati, Parul; Suri, Ajit; Lin, Tiffany; Vasudevan, Raghavan; Rosario, Maria Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 7(2021) Page Start: 734 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study. (17th March 2022) Authors: Hyams, Jeffrey S; Turner, Dan; Cohen, Stanley A; Szakos, Erzsébet; Kowalska-Duplaga, Kinga; Ruemmele, Frank; Croft, Nicholas M; Korczowski, Bartosz; Lawrence, Promise; Bhatia, Siddharth; Kadali, Harisha; Chen, Chunlin; Sun, Wan; Rosario, Maria; Kabilan, Senthil; Treem, William; Rossiter, Guillerm... Journal: Journal of Crohn's and colitis Issue: Volume 16:Number 8(2022) Page Start: 1243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S0876 Assessment of Vedolizumab Disease-Drug-Drug Interaction in Patients With Inflammatory Bowel Diseases. (October 2020) Authors: Sun, Wan; Lirio, Richard A.; Schneider, Jennifer; Aubrecht, Jiri; Kadali, Harisha; Baratta, Mike; Gulati, Parul; Suri, Ajit; Lin, Tiffany; Vasudevan, Raghavan; Rosario, Maria Journal: American journal of gastroenterology Issue: Volume 115:Supplement(2020)ACG Annual Meeting Abstracts 1 Page Start: S451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗